The global Short Bowel Syndrome market is expected to increase at a CAGR of 16.2% between 2024 and 2031, reaching USD 4.6 billion from USD 1.5 billion in 2024.
North America dominates the market, accounting for over 45% of the total worldwide share. Key metrics include increasing prevalence of short bowel syndrome, expanding uptake of innovative therapies, and rising investments in R&D.ment of targeted therapies for intestinal failure.
Market Trend: Advancements in intestinal rehabilitation therapies and tissue engineering
The Short Bowel Syndrome (SBS) market is seeing a substantial shift towards the development of improved intestinal rehabilitation therapies and tissue engineering techniques. Recent advances include the investigation of regenerative medicine approaches for producing functioning intestinal tissue in vitro for transplantation. For example, in 2023, a breakthrough study reported the effective generation of mini-intestines from stem cells, indicating the possibility of future autologous intestinal tissue transplants.
In addition, there is growing interest in bioengineered intestinal grafts, which have the potential to repair or augment damaged gut sections. The trend extends to the development of innovative nutritional formulations and feeding regimens aimed at improving gut adaptability and function in SBS patients. These improvements aim to lessen the need for parenteral nourishment and improve the quality of life for individuals with severe intestinal failure.
Market Driver: Increasing approval and adoption of targeted therapies for Short Bowel Syndrome
The approval and increasing usage of targeted medicines intended specifically for Short Bowel Syndrome is a major driver of market expansion. In recent years, numerous revolutionary drugs for SBS treatment have acquired regulatory approval, providing new hope to patients who previously had few therapeutic alternatives. For example, glucagon-like peptide-2 (GLP-2) analogues have demonstrated great efficacy in enhancing intestinal absorption and reducing the need for parenteral nourishment in SBS patients. The success of these focused medicines has prompted additional research into innovative drugs that target specific components of intestinal failure and adaptability.
Furthermore, better understanding of the pathophysiology of SBS has resulted in the development of pipeline medications that target several molecular pathways. involved in intestine growth and function. This evolving therapeutic landscape not only improves patient outcomes, but it also drives market growth as healthcare professionals incorporate these specialised treatments into SBS management procedures.
Market Restraint: High treatment costs and limited access to specialised care
One of the major constraints in the Short Bowel Syndrome market is the high expense of therapy, particularly for sophisticated therapies and long-term parenteral feeding assistance. The chronic nature of SBS frequently necessitates lifelong therapy, leading to significant cumulative healthcare costs for patients and healthcare systems. Specialised drugs for SBS, like GLP-2 analogues, can be exceedingly expensive, potentially limiting access for some patients, particularly in areas with less complete healthcare coverage.
Furthermore, the management of SBS necessitates a multidisciplinary strategy involving specialised healthcare practitioners, which may not be available in all geographical areas. The requirement for continued nutritional care, repeated hospitalisations, and potential consequences increase the overall therapeutic burden. These high prices and the requirement for specialised care can result in differences in treatment access and quality, thereby affecting patient outcomes and market growth in specific regions. Addressing these economic and accessibility issues remains critical to the widespread acceptance of modern SBS therapies and the market's overall growth.
Nutritional Therapy Segment:
The nutritional therapy sector dominates the Short Bowel Syndrome market, accounting for around YY% of total global market share. This segment's prominence stems from the crucial function of nutritional assistance in SBS management, particularly parenteral nutrition (PN) and enteral nutrition (EN). Nutritional therapy is frequently the primary and most effective long-term management method for patients with SBS, with the goal of ensuring proper hydration, electrolyte balance, and nutritional status.
Recent innovations in this area have centred on enhancing the formulation of parenteral nutrition solutions and establishing novel enteral feeding protocols. For example, in 2023, a leading nutritional business launched a lipid emulsion exclusively for SBS patients, claiming enhanced fatty acid utilisation and fewer liver problems associated with long-term PN use.
The concept towards personalised nutrition has also gained ground in the SBS market. In 2022, a major healthcare technology company introduced an AI-powered platform for optimising parenteral nutrition prescriptions based on individual patient data and outcomes, with the potential to improve the efficacy and safety of nutritional therapy in SBS management.
Dominating Region: North America
North America dominates the worldwide Short Bowel Syndrome market, thanks to sophisticated healthcare infrastructure, increased awareness among healthcare providers, and favourable reimbursement policies for uncommon diseases.
The region's supremacy is due to a number of reasons, including the presence of major pharmaceutical companies investing in SBS research, a well-established regulatory framework for orphan drug development, and a significant emphasis on rare illness management. The United States has been at the forefront of approving breakthrough SBS therapies and implementing thorough care protocols for intestinal failure patients.
The FDA has granted breakthrough therapy designation to a novel SBS cell therapy, underscoring North America's continued leadership in developing innovative treatments for this rare disorder.
North America accounts for over YY% of the global Short Bowel Syndrome market. The region is expected to retain a robust CAGR of 17.5% throughout the forecast period. The United States has the largest single-country market for SBS medicines, predicted to be worth USD YY million in 2024.
The global Short Bowel Syndrome market is characterised by the existence of a few prominent competitors competing on therapeutic efficacy, drug delivery innovation, and comprehensive patient support programs. Leading firms, including Takeda Pharmaceutical Company Limited, Zealand Pharma A/S, and VectivBio AG, have considerable market shares, accounting for more than 50% of the global market.
The main firms have made significant investments in R&D, with some dedicating up to 20% of their turnover to rare illness research, including SBS. For example, Takeda reported a 25% increase in R&D expenditure on gastrointestinal medicines in the previous fiscal year, with a strong emphasis on expanding its SBS pipeline.
The competitive landscape has recently shifted towards creating long-acting versions of GLP-2 analogues to promote patient comfort and adherence. Several businesses have declared plans to extend their rare illness portfolios through strategic acquisitions and licensing agreements, which could bring new technologies to the SBS market.
In terms of market tactics, leading players are increasingly taking a patient-centric approach, providing full support programs such as dietary counselling, home care services, and financial aid for expensive therapies. For example, a major SBS medication maker recently introduced a digital health platform to help patients manage their conditions and optimize their treatment regimes.
Looking ahead, the competitive landscape is projected to change with the introduction of new therapeutic modalities, such as cell therapies and tissue-engineered products for intestinal rehabilitation. However, existing firms are likely to maintain their dominance due to their excellent clinical development capabilities, substantial distribution networks, and comprehensive awareness of the complex SBS patient experience.
The Short Bowel Syndrome market is expected to develop and innovate significantly in the next few years, driven by advances in targeted therapeutics, increased acknowledgement of SBS as a crucial rare disease, and more investment in regenerative medicine techniques for intestinal failure. Improving diagnostic rates and developing more patient-friendly drug delivery technologies will help the market grow even faster.
The rise of microbiome-based therapeutics for SBS management is an interesting trend to note. Research is being conducted to produce probiotic and prebiotic formulations specifically designed to improve gut adaptability and reduce problems in SBS patients. This tendency could open up new therapy options, potentially providing synergistic effects when paired with established pharmaceutical and nutritional interventions.
However, the market faces obstacles due to the high cost of innovative therapies and the requirement for long-term safety evidence on emerging treatments. To overcome these concerns, industry actors should prioritise the development of cost-effective treatment options as well as extensive long-term research to demonstrate treatment advantages' durability. Furthermore, there is a rising need for increased global knowledge and education regarding SBS among healthcare providers in order to ensure timely diagnosis and adequate treatment.
To summarise, while the Short Bowel Syndrome market is a niche segment of the pharmaceutical industry, its future growth will be dependent on continued therapeutic innovation, improved patient access to specialised care, and successful demonstration of the long-term clinical and economic benefits of advanced therapies. Industry participants who can successfully solve these issues while navigating the intricacies of rare illness drug research and commercialisation are likely to prosper in this high-potential industry.
Takeda Pharmaceutical Company Limited
Zealand Pharma A/S
VectivBio AG
Shire plc (now part of Takeda)
Nutrinia Ltd.
OxThera AB
Naia Pharmaceuticals, Inc.
Gelesis, Inc.
Emmaus Life Sciences, Inc.
Ardelyx, Inc.
July 2023: VectivBio AG revealed encouraging Phase 3 findings for its lead candidate in adult SBS patients, indicating considerable reductions in parenteral support requirements.
Zealand Pharma A/S announced the start of a Phase 2 trial for a novel, long-acting GLP-2 analogue in February 2024, with the goal of providing SBS patients with less frequent treatment.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. Takeda Pharmaceutical Company Limited
5.2. Zealand Pharma A/S
5.3. VectivBio AG
5.4. Shire plc (now part of Takeda)
5.5. Nutrinia Ltd.
5.6. OxThera AB
5.7. Naia Pharmaceuticals, Inc.
5.8. Gelesis, Inc.
5.9. Emmaus Life Sciences, Inc.
5.10. Ardelyx, Inc.
5.11. Company name 11
5.12. Company name 12 (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Advancements in intestinal rehabilitation therapies and tissue engineering
6.1.2. Emergence of microbiome-based therapies for SBS management
6.1.3. Development of long-acting formulations for improved patient convenience
6.2. Market Drivers
6.2.1. Increasing approval and adoption of targeted therapies for Short Bowel Syndrome
6.2.2. Rising prevalence and improved diagnosis of SBS
6.2.3. Growing investments in rare disease research and development
6.3. Market Restraints
6.3.1. High treatment costs and limited access to specialised care
6.3.2. Challenges in conducting clinical trials for rare diseases
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TREATMENT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Nutritional Therapy
7.1.1. Parenteral Nutrition
7.1.2. Enteral Nutrition
7.2. Medication
7.2.1. GLP-2 Analogues
7.2.2. Growth hormones
7.3. Surgery
7.3.1. Intestinal Transplantation
7.3.2. Autologous gastrointestinal reconstructive surgery
8. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH)--2020-2031)
8.1. Hospital Pharmacies
8.1.1. Inpatient Pharmacies
8.1.2. Outpatient Pharmacies
8.2. Retail Pharmacies
8.2.1. Chain Pharmacies
8.2.2. Independent Pharmacies
8.3. Online pharmacies
8.3.1. E-commerce Platforms
8.3.2. Direct-to-patient services
9. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospitals
9.1.1. Inpatient Care
9.1.2. Outpatient Clinics
9.2. Homecare Settings
9.2.1. Home Parenteral Nutrition
9.2.2. Home Enteral Nutrition
9.3. Speciality Clinics
9.3.1. Gastroenterology Clinics
9.3.2. Nutrition Support Clinics
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of the Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%, YOY GROWTH)--2020-2031.
By Treatment Type:
Nutritional Therapy
Medication
Surgery
By Distribution Channel:
Hospital Pharmacies
Retail pharmacies
Online pharmacies
By End User:
Hospitals
Homecare Settings
Speciality Clinics
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
